Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform

Rhea-AI Summary

Polyrizon (Nasdaq: PLRZ) announced publication of U.S. patent application US 2024/0358741 A1 for its Trap & Target™ mucoadhesive polymer platform for nasal drug delivery.

The biocompatible hydrogels aim to enhance mucosal retention, drug absorption, and sprayable film-forming delivery across nasal and other mucosal routes.

News Market Reaction – PLRZ

+15.55% 2.5x vol

8 alerts

+15.55% Session close to close

+26.6% Peak in 6 hr 14 min

$27.36M Market Cap

2.5x Rel. Volume

In the Jun 17 session, PLRZ gained 15.55%, reflecting a significant positive market reaction. Argus tracked a peak move of +26.6% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. Trading volume was elevated at 2.5x the daily average, suggesting notable buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +15.6% in the session following this news. A strong positive reaction aligns with P...

Analysis

The stock surged +15.6% in the session following this news. A strong positive reaction aligns with Polyrizon’s ongoing efforts to build its intellectual property around intranasal hydrogels. The U.S. patent publication supports earlier European patent steps and clinical site agreements, reinforcing the Trap & Target™ platform story. Investors have seen mixed follow-through after prior good news, and the existing $50,000,000 shelf registration could remain a factor when assessing future capital needs.

Key Figures

U.S. patent application: US 2024/0358741 A1

1 metrics

U.S. patent application US 2024/0358741 A1 Mucoadhesive polymers for nasal drug delivery

Historical Context

5 past events · Latest: Jun 15 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 15	Human study setup	Positive	-2.7%	Agreements for European human study to measure NASARIX nasal residence time.
Jun 10	European patent step	Positive	-3.4%	European publication preparations for Trap & Target mucoadhesive patent application.
Jun 08	Clinical sites added	Positive	+0.3%	Agreements securing three major U.S. centers for NASARIX allergy trial.
May 13	First US trial site	Positive	+1.1%	First U.S. clinical trial agreement for NASARIX Allergy Blocker study.
May 11	Platform promo	Positive	-1.4%	Paid promotional piece on Capture&Contain intranasal antiviral hydrogel platform.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent Polyrizon headlines tended to be positive but often saw flat-to-negative next-day moves, indicating a pattern of muted or fading reactions to good news.

Recent Company History

Over the past months, Polyrizon has repeatedly updated the market on its nasal drug delivery platforms and NASARIX™ (PL-14) program. On May 13 and June 8, it reported securing U.S. clinical sites, while a June 15 update detailed a European human characterization study. On June 10, the company highlighted European patent publication for its mucoadhesive technology, and a May 11 promotional piece described its Capture&Contain™ platform. Despite generally constructive news, price reactions often skewed negative.

Key Terms

mucoadhesive, nasal mucosa, biocompatible, sulfated polysaccharides, +4 more

8 terms

mucoadhesive medical

"titled “Mucoadhesive Polymers for Nasal Drug Delivery”. The patent application covers"

Mucoadhesive describes a material or drug formulation that sticks to mucous membranes—surfaces like the inside of the mouth, nose, throat or gut—to stay in place longer and release medicine locally or more steadily. For investors, mucoadhesive properties can improve a product's effectiveness, dosing convenience and competitive differentiation, influencing clinical success, regulatory review and commercial value much like a bandage that holds medicine against a wound for longer, increasing its benefit.

nasal mucosa medical

"enhance the interaction between pharmaceutical formulations and the nasal mucosa, potentially"

The nasal mucosa is the soft, moist lining inside the nose that produces mucus and acts like a protective carpet or sponge, trapping particles and helping control moisture and air flow. For investors, its condition determines how well nasal drugs, vaccines or diagnostic swabs are absorbed and tolerated, so findings about irritation, effectiveness, or delivery can materially affect regulatory approval, market potential and commercial success of related products.

biocompatible medical

"describes biocompatible mucoadhesive compositions designed to form a uniform and"

A biocompatible material or product can be placed in or used on the human body without causing harmful reactions, irritation, or rejection; it’s the quality that allows medical devices, implants, or drug-delivery systems to coexist safely with tissues and bodily fluids. Investors care because proven biocompatibility is a key hurdle for regulatory approval, patient and clinician acceptance, and lower recall or liability risk—like clothing that won’t irritate skin, it helps products reach the market faster and sell more reliably.

sulfated polysaccharides medical

"technology combines sulfated polysaccharides, with hydrophilic polymers, partially crosslinked"

Long chains of sugar molecules that carry negatively charged sulfate groups, sulfated polysaccharides act like a string of beads with sticky tags that change how they interact with cells, proteins and viruses. Investors should care because these biologic compounds are used as active ingredients or excipients in drugs, diagnostics and medical devices, and their unique chemistry affects therapeutic potential, manufacturing complexity, regulatory review and intellectual property value.

hydrophilic polymers medical

"combines sulfated polysaccharides, with hydrophilic polymers, partially crosslinked with"

Hydrophilic polymers are plastic-like materials that attract and hold water, behaving more like a soft sponge than a hard plastic. In healthcare and product manufacturing they are used in drug delivery systems, contact lenses, wound dressings and surface coatings to control moisture, release medicines or improve compatibility with the body. Investors care because these materials affect product performance, regulatory approval, manufacturing complexity and market acceptance, which all influence commercial value and risk.

crosslinked technical

"with hydrophilic polymers, partially crosslinked with divalent ions to create formulations"

Crosslinked describes a material—often a polymer used in drugs, medical devices, or packaging—whose long chains are joined together by chemical bonds to form a network, like threads stitched into a net. That change in structure can make a product firmer, more stable, slower to break down, or controlled in how it releases an active ingredient, so investors watch crosslinking because it can affect a product’s performance, manufacturing complexity, regulatory review, patent protection and market value.

bioavailability medical

"with the goal of improving mucosal retention and bioavailability."

Bioavailability is the measure of how much and how quickly a substance, such as a medication or nutrient, enters the bloodstream and becomes available for use by the body. For investors, it matters because it influences how effectively a product works and how quickly results are seen, which can impact a company's success and the potential value of related investments. Think of it like how much of a medicine actually reaches your bloodstream after taking it—that determines how well it can do its job.

therapeutic agents medical

"systemic administration of therapeutic agents through mucosal tissues. According to"

Therapeutic agents are drugs, vaccines or other medical treatments designed to prevent, relieve, or cure disease. For investors they matter because each agent represents a potential product that can generate revenue, face regulatory approval hurdles, and influence a company’s valuation—think of them as new tools in a toolbox where success or failure determines whether the tool becomes a valuable asset or a costly experiment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Raanana, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the publication of U.S. patent application No. US 2024/0358741 A1, titled “Mucoadhesive Polymers for Nasal Drug Delivery”.

The patent application covers Polyrizon’s proprietary Trap & Target™ (T&T) mucoadhesive polymer technology platform for nasal drug delivery. The technology is designed to enhance the interaction between pharmaceutical formulations and the nasal mucosa, potentially increasing formulation retention, improving drug absorption, and enabling more efficient delivery of active pharmaceutical ingredients through the nasal route.

The published patent application describes biocompatible mucoadhesive compositions designed to form a uniform and durable film on mucosal surfaces while enabling enhanced delivery and retention of pharmaceutical actives. The technology combines sulfated polysaccharides, with hydrophilic polymers, partially crosslinked with divalent ions to create formulations with improved viscosity, sprayability, and film-forming properties.

The patent application further outlines the potential use of the platform in oral and nasal drug delivery systems, including sprays, gels, inhalation products, and formulations intended for localized and systemic administration of therapeutic agents through mucosal tissues.

According to the application, the platform may support delivery of a broad range of therapeutic compounds, including anti-inflammatory drugs, vaccines, biologics, and additional pharmaceutical actives, with the goal of improving mucosal retention and bioavailability.

About Polyrizon

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain ^TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target, or T&T. For more information, please visit https://polyrizon-biotech.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential uses and benefits of its technology. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.

Contacts:

Michal Efraty
Investor Relations
IR@polyrizon-biotech.com

FAQ

What U.S. patent publication did Polyrizon (PLRZ) announce on June 17, 2026?

Polyrizon announced publication of U.S. patent application US 2024/0358741 A1 for mucoadhesive polymers for nasal drug delivery. According to Polyrizon, the filing covers its Trap & Target™ platform for enhancing interaction between intranasal formulations and the nasal mucosa.

What is Polyrizon's Trap & Target™ mucoadhesive drug delivery platform?

Trap & Target™ is a proprietary mucoadhesive polymer platform designed to improve nasal drug delivery. According to Polyrizon, it enhances interaction with nasal mucosa, aiming to increase formulation retention, drug absorption, and efficient delivery of active pharmaceutical ingredients through the nasal route.

How does Polyrizon's mucoadhesive platform work to improve nasal drug delivery?

Polyrizon’s platform uses biocompatible mucoadhesive compositions that form a uniform, durable film on mucosal surfaces. According to Polyrizon, sulfated polysaccharides and hydrophilic polymers, partially crosslinked with divalent ions, create formulations with improved viscosity, sprayability, and film-forming properties for nasal drug delivery.

Which types of therapies could Polyrizon's Trap & Target™ platform deliver?

The platform may support delivery of diverse therapeutic compounds including anti-inflammatory drugs, vaccines, biologics, and other actives. According to Polyrizon, it is designed to improve mucosal retention and bioavailability, potentially benefiting both localized and systemic administration of these therapeutic agents.

Beyond nasal sprays, what dosage forms could use Polyrizon's mucoadhesive technology?

Polyrizon’s platform is outlined for use in nasal and oral drug delivery systems. According to Polyrizon, potential formats include sprays, gels, inhalation products, and other formulations intended for localized and systemic delivery through mucosal tissues.

Is Polyrizon's mucoadhesive drug delivery platform limited to nasal administration?

No, the platform is described for nasal and oral delivery, and broader mucosal use. According to Polyrizon, it targets localized and systemic administration via mucosal tissues, using film-forming compositions to enhance retention and delivery of active pharmaceutical ingredients.